Branding/Logomark minus Citation Combined Shape Icon/Bookmark-empty Icon/Copy Icon/Collection Icon/Close Copy 7 no author result Created with Sketch. Icon/Back Created with Sketch. Match!
Inge B. Halberg
Novo Nordisk
3Publications
1H-index
5Citations
Publications 3
Newest
Published on May 8, 2019in Diabetes, Obesity and Metabolism 6.13
Thomas R. Pieber61
Estimated H-index: 61
(University of Graz),
Eva Svehlikova2
Estimated H-index: 2
(University of Graz)
+ 3 AuthorsHanne Haahr18
Estimated H-index: 18
(Novo Nordisk)
Source Cite
Published on May 16, 2019in Clinical Pharmacokinectics 4.68
Inge B. Halberg1
Estimated H-index: 1
,
Karsten Lyby5
Estimated H-index: 5
+ 3 AuthorsEric Zijlstra10
Estimated H-index: 10
Source Cite
Published on Mar 1, 2019in The Lancet Diabetes & Endocrinology 24.54
Inge B. Halberg1
Estimated H-index: 1
(Novo Nordisk),
Karsten Lyby5
Estimated H-index: 5
(Novo Nordisk)
+ 3 AuthorsLeona Plum-Mörschel5
Estimated H-index: 5
Summary Background Oral insulin 338 (I338) is a long-acting, basal insulin analogue formulated in a tablet with the absorption-enhancer sodium caprate. We investigated the efficacy and safety of I338 versus subcutaneous insulin glargine (IGlar) in patients with type 2 diabetes. Methods This was a phase 2, 8-week, randomised, double-blind, double-dummy, active-controlled, parallel trial completed at two research institutes in Germany. Insulin-naive adult patients with type 2 diabetes, inadequatel...
6 Citations Source Cite
1